|
|
||||||||
The Second Department of Internal Medicine, Yamaguchi University School of Medicine, Ube 755-8505, Japan
| |
ABSTRACT |
|---|
|
|
|---|
To investigate the role of protein kinase C (PKC) in the mechanism of ischemic preconditioning (IP), infarct size and the incidence of apoptosis caused by ischemia-reperfusion were tested in four groups of Sprague-Dawley rats. Dimethyl sulfoxide (vehicle) or calphostin C (0.1 mg/ml) was administered 5 min before the 30-min coronary occlusion followed by a 6-h reperfusion. Three cycles of 3 min of ischemia followed by 3 min of reperfusion was performed as IP before the 30-min ischemia followed by a 6-h reperfusion with or without calphostin C pretreatment. Infarct size defined by triphenyltetrazolium chloride staining was reduced from 60 ± 2 to 26 ± 2% by IP (P < 0.01), but the effect of IP was abolished by calphostin C (51 ± 3%). Apoptosis defined by in situ terminal deoxynucleotidyl transferase end-labeling (TUNEL) was reduced by IP from 44 ± 3 to 13 ± 2% in the subendocardial region (P < 0.01). This effect of IP was abolished by calphostin C (42 ± 8%). Thus the effect of IP on reducing the infarct size and the incidence of apoptosis are both mediated by PKC in rat hearts.
infarct size; calphostin C
| |
INTRODUCTION |
|---|
|
|
|---|
APOPTOTIC CELL DEATH is characterized morphologically by chromatin condensation and biochemically by fragmentation of internucleosomal DNA to multiples of 180-200 bp fragments (28). Recently, Gottlieb et al. (8) showed that apoptotic cell death as well as necrosis occurs in myocytes subjected to ischemia-reperfusion insult in rabbit hearts. We and others (22, 24) have previously reported that a transient preceding ischemia termed ischemic preconditioning reduced both myocardial infarct size and the incidence of apoptosis. However, the underlying mechanism by which ischemic preconditioning reduces apoptosis induced by ischemia-reperfusion has remained to be clarified.
Ischemic preconditioning is a phenomenon where a series of brief periods of myocardial ischemia-reperfusion increase myocardial tolerance to the subsequent prolonged ischemia. Since this phenomenon was first reported in 1986 by Murry et al. (20), the mechanism of ischemic preconditioning has been intensively studied, and it is believed that the activation of protein kinase C (PKC) plays a pivotal role in mediating ischemic preconditioning (10, 15, 31). However, the role of PKC in the mechanism of ischemic preconditioning attenuating apoptosis remains unknown.
Thus the purpose of the present study was to clarify the role of PKC in the mechanism of reducing apoptosis by ischemic preconditioning.
| |
METHODS |
|---|
|
|
|---|
Animal preparation. All experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 86-23), and the protocol was approved by the Animal Research Committee of Yamaguchi University School of Medicine. Male Sprague-Dawley rats weighing 280-330 g were anesthetized by intraperitoneal injection of pentobarbital sodium (60 mg/kg). Additional anesthesia was supplied during the experiment if necessary. Rats were intubated and ventilated with a respirator using a mixture of 100% oxygen and room air (tidal volume, 1.2 ml/100 g body wt; respiratory rate, 65-70 breaths/min). Arterial blood gases were monitored, and arterial PO2, PCO2, and pH were maintained within the physiological range. Left thoracotomy was performed in the fourth intercostal space, and the heart was exposed. A 6-0 silk thread was passed around the left anterior descending coronary artery using a tapered needle. Both ends of the thread were passed through a 1-cm length polyethylene tube (outer diameter 1.5 mm) to occlude and reperfuse the coronary artery. Left ventricular pressure was measured by a 2-F. catheter-tip manometer (model SPC-320, Millar Instruments) inserted via the right carotid artery. Myocardial ischemia was confirmed by the bulging of the relevant segment of the left ventricle, the increase of the left ventricular end-diastolic pressure, and the S-T segment elevation in the electrocardiogram. The body temperature was measured by an electric thermistor and maintained at 37 ± 0.5°C with a heating pad placed under the rat.
Heart rate, peak and end-diastolic left ventricular pressures, the first derivative of the left ventricular pressure (dP/dt), and the time constant of isovolumic left ventricular pressure decay calculated by a monoexponential model without asymptote were measured (5).
Reagents. Calphostin C (Kyowa Medex, Tokyo, Japan) is a specific inhibitor of PKC (13). It was dissolved in DMSO at a concentration of 2 mg/ml, and the solution was diluted with sterilized water to the concentration of 0.1 mg/ml before use.
Experimental protocol. Rats were
randomly assigned to one of the following four groups (Fig.
1). In all groups rats were subjected to 30 min of coronary occlusion followed by a 6-h reperfusion period. In the
vehicle group (control; n = 7), 0.3 ml
of 5% DMSO was administered intravenously 5 min before the 30-min
coronary occlusion. In the calphostin C group (Cal;
n = 7), calphostin C (0.1 mg/kg) was
administered intravenously 5 min before the 30-min coronary occlusion.
In the ischemic preconditioning group (IP;
n = 7), three cycles of 3 min of
ischemia followed by 3 min of reperfusion was performed as
ischemic preconditioning before the 30-min coronary occlusion. In the
ischemic preconditioning + calphostin C group (IP + Cal;
n = 7), calphostin C (0.1 mg/kg) was
administered 5 min before the ischemic preconditioning followed by the
30 min of ischemia. After the 6-h reperfusion period, rats were
euthanized with an overdose of the anesthetic.
|
Definition of area at risk and area of infarction. After the rats were euthanized, the left anterior descending coronary artery was reoccluded and the heart was excised. Monastral blue dye (1.5%, 1 ml) was injected into the ascending aorta to delineate the risk area as a perfusion defect. The heart was then sliced into 1-mm thick sections, and the slices were incubated in 1% triphenyltetrazolium chloride (TTC) at 37°C for 20 min. Viable myocardium is stained in red by TTC, whereas infarcted tissue remains unstained (27). The slices were imaged in color at four times the magnification by a charge-coupled digital camera (FV-10, Fuji Photo Film, Japan), and stored on a Macintosh computer for image analysis. The area stained by the blue dye (perfused area), the unstained area (area at risk; AR), and the area of infarcted (AI) and noninfarcted myocardium were defined using an image analysis software (NIH Image). The AR normalized by the left ventricular area (AR/LV), and the AI normalized by the AR (AI/AR) were calculated. The heart slices were fixed with 10% Formalin and embedded in paraffin for subsequent in situ nick end labeling (TUNEL).
In situ nick end labeling. The TUNEL protocol was based on the previously published procedure (6). It depends on the preferential labeling by terminal deoxynucleotidyl transferase of 3'-OH ends of DNA. In brief, 4-µm thick sections of the heart were deparaffinized by a xylene wash and a descending ethanol series (100%, 95%, 70%, and 0%) and then washed with phosphate-buffered saline. The sections were subsequently incubated with 20 µg/ml proteinase K for 15 min at room temperature, and endogenous peroxidase was inactivated by the treatment with 3% hydrogen peroxide for 5 min. Equilibration buffer (42 µl) was then added to the sections and incubated with terminal deoxynucleotidyl transferase (ApopTag, Oncor) for 1.5 h at 37°C. After end labeling was completed, the sections were incubated with anti-digoxygenin peroxidase for 30 min at room temperature. For the color development, 3% aminoethylcarbazole was applied to the section for 3 min at room temperature. Finally, the sections were counterstained with hematoxylin. After the procedures, 1,000 nuclei in the subendo-, mid-, and subepicardial regions in the risk area were examined by microscopy at a magnification of ×200, and the number of TUNEL-positive myocyte nuclei was counted and expressed as a percentage of the total number of myocyte nuclei in each region (%AP).
Agarose gel electrophoresis of DNA. In
the separate series of experiments, the same protocol
(n = 5, each) was carried out for the
detection of DNA ladder. Transmural myocardial samples from ischemic
and nonischemic areas were isolated, frozen in liquid nitrogen, and
stored at
80°C. The DNA was extracted from 70-80 mg of
nonrisk and risk area of the left ventricular myocardium using a
nucleic acid extraction kit (IsoQuick, Microprobe). The concentration
of DNA in each sample was measured by spectrophotometry (260 nm). A
same amount (10 µg) of extracted DNA was loaded on a 2.0% agarose
gel containing ethidium bromide in 0.04 mol/l Tris, 0.04 mol/l borate
acid, 2 mmol/l EDTA, pH 8.0 (TBE), and electrophoresed on a flatbed gel
apparatus (Mupid-3, ADVANCE, Japan) at 100 V. The gel was photographed
under transmitted ultraviolet light.
Statistical analysis. All values are expressed as means ± SE. The hemodynamic changes were assessed by a two-way ANOVA with repeated measure, and Fisher's test was used for multiple comparisons when a significant F value was obtained. Intergroup differences in AR/LV, AI/AR, and the percentage of TUNEL-positive myocyte nuclei were analyzed by one-way ANOVA, and Fisher's test was used for multiple comparisons. Differences at P < 0.05 were considered significant.
| |
RESULTS |
|---|
|
|
|---|
Hemodynamic responses and arrhythmias.
There were no significant differences in body weight, heart rate, peak
and end-diastolic left ventricular pressures, LV
+dP/dt, and the time constant between the groups before and during the 30-min coronary occlusion and at 10 min after the reperfusion (Table 1). All
rats of control, Cal, and IP + Cal groups showed arrhythmias such as
ventricular tachycardia during the 30 min of ischemia,
especially during the initial 5-10 min of ischemia,
whereas the incidence of ventricular tachycardia was markedly reduced
in the IP group.
|
Myocardial infarct size. Figures
2 and 3 show results of
AR/LV and AI/AR. AR/LV did not differ significantly among the groups (51 ± 2% in the control group, 59 ± 3% in the Cal group, 47 ± 4% in the IP group, 48 ± 3% in the IP + Cal group, NS).
However, AI/AR was significantly smaller in the IP group (26 ± 2%)
than in the other three groups (60 ± 2% in the control group,
63 ± 2% in the Cal group, 51 ± 3% in the IP + Cal
group, P < 0.01 vs. IP,
respectively).
|
|
Count of myocytes with TUNEL-positive
nuclei. TUNEL-positive myocyte nuclei were counted in
the histological sections. Figure 4 shows
TUNEL-positive nuclei at a magnification of ×200. We counted myocyte nuclei stained by hematoxylin or TUNEL. The TUNEL-positive nuclei were observed only in the risk area and were mainly located in
the subendocardial region.
|
Figure 5 shows %AP in the subendocardial
region. The %AP was reduced significantly by ischemic preconditioning
(13 ± 2% in the IP group vs. 44 ± 3% in the control group,
P < 0.01), and the effect of
ischemic preconditioning was abolished by the pretreatment of
calphostin C.
|
DNA laddering in agarose gel
electrophoresis. A series of DNA fragments with a size
range in multiples of 180-200 bp of a so-called "ladder
pattern" indicates apoptotic internucleosomal DNA fragmentation. The
ladder pattern was observed in the myocardium from the risk area of
control, Cal, and IP + Cal groups but was less in the IP group compared
with other groups (Fig. 6). No ladder pattern was observed in the myocardium from the nonrisk area of all
groups.
|
| |
DISCUSSION |
|---|
|
|
|---|
The present study demonstrates that ischemic preconditioning reduced both myocardial infarct size and myocyte apoptosis caused by the ischemia-reperfusion insult. This effect of ischemic preconditioning was abolished by a selective PKC inhibitor calphostin C, indicating a crucial role of PKC in the mechanism of ischemic preconditioning.
Mechanism of ischemic preconditioning. Ischemic preconditioning exerts a strong cardioprotective effect against myocardial ischemic insult. This phenomenon has been confirmed in many animal models (14, 16, 18, 20, 23, 25), including human hearts (4, 21, 30). Whereas the mechanism of ischemic preconditioning has not been fully understood, several mediators such as adenosine (17), bradykinin (7), norepinephrine (1), and free radicals (26) have been reported. These mediators initiate intracellular signaling pathways by acting on G protein-linked receptors. Then phospholipase C activated by G proteins produces diacylglycerol, which activates cytosolic PKC (31). The possible end-effectors to induce myocardial protection such as ATP-sensitive potassium channels (10, 29) and the vacuolar proton ATPase may be phosphorylated and activated by PKC (9).
Apoptosis in ischemia-reperfusion insult. Gottlieb et al. (8) reported that the chromatin condensation and nucleosomal ladders were observed in the rabbit myocytes subjected to 30 min of ischemia followed by 4 h of reperfusion, and they indicated that the ischemia-reperfusion injury caused necrosis and apoptosis. Necrosis is characterized by the swelling of mitochondria, loss of plasma membrane integrity, and the random digestion of DNA (3). In contrast, apoptosis is characterized morphologically by a chromatin condensation and biochemically by internucleosomal DNA fragmentation (28). The fragmentation of genomic DNA into nucleosome-sized fragments by the endonucleolytic cleavage is a biochemical hallmark of apoptosis (2).
The present study domonstrates that the myocardial infarct size defined by TTC staining was significantly attenuated by ischemic preconditioning together with a significant reduction of apoptosis. This result is supported by previous studies done by Gottlieb et al. (9) and Piot et al. (22).
PKC and incidence of apoptosis.
Calphostin C is a specific inhibitor of PKC acting on its regulatory
domain (13). We and others (12, 16) have already demonstrated that the
ischemic preconditioning is mediated by PKC, especially by the
translocation of PKC-
and -
, and the effect was blocked by
calphostin C or chelerythrine. The present study demonstrated that the
pretreatment of calphostin C abolished the effect of ischemic
preconditioning on both infarct size and the incidence of apoptosis.
This suggests the pivotal role of PKC in mediating a cardioprotective
effect of ischemic preconditioning not only on infarct size but also on
the incidence of apoptosis. Whereas the underlying mechanism of
reducing apoptosis by ischemic preconditioning is not fully understood, the attenuation of acidosis induced by vacuolar proton ATPase, which is activated by PKC, may be involved (9). The other
possible role of PKC activation in inhibiting apoptosis may
be related to the phosphorylation of anti-apoptotic proteins such as
Bcl-2 and Bcl-x, because the anti-apoptotic effect of these proteins
may depend on its phosphorylation (11, 19).
Further studies are needed to clarify the mechanism of PKC-dependent modulation of apoptosis in ischemia-reperfusion model.
In conclusion ischemic preconditioning reduces apoptosis induced by ischemia-reperfusion insult, and the effect may be mediated by PKC activation during ischemic preconditioning.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Rie Ishihara and Kazuko Iwamoto for excellent technical assistance.
| |
FOOTNOTES |
|---|
This study was supported in part by research Grant 07670785 from the Ministry of Education, Science and Culture of Japan.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: T. Miura, The Second Dept. of Internal Medicine, Yamaguchi Univ. School of Medicine, 1-1-1 Minami, Kogushi, Ube 755-8505, Japan (E-mail: toshiro{at}po.cc.yamaguchi-u.ac.jp).
Received 18 March 1998; accepted in final form 17 June 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Ardell, J. L.,
X. M. Yang,
B. A. Barron,
J. M. Downey,
and
M. V. Cohen.
Endogenous myocardial norepinephrine is not essential for ischemic preconditioning in rabbit heart.
Am. J. Physiol.
270 (Heart Circ. Physiol. 39):
H1078-H1084,
1996
2.
Arends, M. J.,
R. G. Morris,
and
A. H. Wyllie.
Apoptosis. The role of the endonuclease.
Am. J. Pathol.
136:
593-608,
1990[Abstract].
3.
Darzynkiewicz, Z.,
S. Bruno,
G. Del Bino,
W. Gorczyca,
M. A. Hotz,
P. Lassota,
and
F. Traganos.
Features of apoptotic cells measured by flow cytometry.
Cytometry
13:
795-808,
1992[Medline].
4.
Deutsch, E.,
M. Berger,
W. G. Kussmaul,
J. W. Hirshfeld, Jr.,
H. C. Herrmann,
and
W. K. Laskey.
Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features.
Circulation
82:
2044-2051,
1990
5.
Gaasch, W. H.,
A. S. Blaustein,
C. W. Andrias,
R. P. Donahue,
and
B. Avitall.
Myocardial relaxation. II. Hemodynamic determinants of rate of left ventricular isovolumic pressure decline.
Am. J. Physiol.
239 (Heart Circ. Physiol. 8):
H1-H6,
1980.
6.
Gavrieli, Y.,
Y. Sherman,
and
S. A. Ben Sasson.
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
J. Cell Biol.
119:
493-501,
1992
7.
Goto, M.,
Y. Liu,
X. M. Yang,
J. L. Ardell,
M. V. Cohen,
and
J. M. Downey.
Role of bradykinin in protection of ischemic preconditioning in rabbit hearts.
Circ. Res.
77:
611-621,
1995
8.
Gottlieb, R. A.,
K. O. Burleson,
R. A. Kloner,
B. M. Babior,
and
R. L. Engler.
Reperfusion injury induces apoptosis in rabbit cardiomyocytes.
J. Clin. Invest.
94:
1621-1628,
1994.
9.
Gottlieb, R. A.,
D. L. Gruol,
J. Y. Zhu,
and
R. L. Engler.
Preconditioning rabbit cardiomyocytes: role of pH, vacuolar proton ATPase, and apoptosis.
J. Clin. Invest.
97:
2391-2398,
1996[Medline].
10.
Gross, G. J.,
and
J. A. Auchampach.
Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs.
Circ. Res.
70:
223-233,
1992
11.
Horiuchi, M.,
W. Hayashida,
T. Kambe,
T. Yamada,
and
V. J. Dzau.
Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis.
J. Biol. Chem.
272:
19022-19026,
1997
12.
Kawamura, S.,
K. Yoshida,
T. Miura,
Y. Mizukami,
and
M. Matsuzaki.
Ischemic preconditioning translocates PKC-
and -
, which mediate functional protection in isolated rat heart.
Am. J. Physiol.
275 (Heart Circ. Physiol. 44):
H2266-H2271,
1998
13.
Kobayashi, E.,
H. Nakano,
M. Morimoto,
and
T. Tamaoki.
Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C.
Biochem. Biophys. Res. Commun.
159:
548-553,
1989[Medline].
14.
Li, G. C.,
J. A. Vasquez,
K. P. Gallagher,
and
B. R. Lucchesi.
Myocardial protection with preconditioning.
Circulation
82:
609-619,
1990
15.
Li, Y.,
and
R. A. Kloner.
Does protein kinase C play a role in ischemic preconditioning in rat hearts?
Am. J. Physiol.
268 (Heart Circ. Physiol. 37):
H426-H431,
1995
16.
Li, Y. W.,
P. Whittaker,
and
R. A. Kloner.
The transient nature of the effect of ischemic preconditioning on myocardial infarct size and ventricular arrhythmia.
Am. Heart J.
123:
346-353,
1992[Medline].
17.
Liu, G. S.,
J. Thornton,
D. M. Van Winkle,
A. W. Stanley,
R. A. Olsson,
and
J. M. Downey.
Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart.
Circulation
84:
350-356,
1991
18.
Liu, Y.,
and
J. M. Downey.
Ischemic preconditioning protects against infarction in rat heart.
Am. J. Physiol.
263 (Heart Circ. Physiol. 32):
H1107-H1112,
1992
19.
Maulik, N.,
M. Watanabe,
Y. L. Zu,
C. K. Huang,
G. A. Cordis,
J. A. Schley,
and
D. K. Das.
Ischemic preconditioning triggers the activation of MAP kinases and MAPKAP kinase 2 in rat hearts.
FEBS Lett.
396:
233-237,
1996[Medline].
20.
Murry, C. E.,
R. B. Jennings,
and
K. A. Reimer.
Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.
Circulation
74:
1124-1136,
1986
21.
Ottani, F.,
M. Galvani,
D. Ferrini,
F. Sorbello,
P. Limonetti,
D. Pantoli,
and
F. Rusticali.
Prodromal angina limits infarct size. A role for ischemic preconditioning.
Circulation
91:
291-297,
1995
22.
Piot, C. A.,
D. Padmanaban,
P. C. Ursell,
R. E. Sievers,
and
C. L. Wolfe.
Ischemic preconditioning decreases apoptosis in rat hearts in vivo.
Circulation
96:
1598-1604,
1997
23.
Schott, R. J.,
S. Rohmann,
E. R. Braun,
and
W. Schaper.
Ischemic preconditioning reduces infarct size in swine myocardium.
Circ. Res.
66:
1133-1142,
1990
24.
Shirakawa, K.,
T. Miura,
K. Yamakawa,
S. Kawamura,
H. Tatsuno,
A. Fujii,
Y. Nakamura,
T. Ryoke,
and
M. Matsuzaki.
Effect of ischemic preconditioning on the expression of TNF-
and the induction of apoptosis in the ischemia-reperfused rat heart (Abstract).
Circulation
92:
I-773,
1995.
25.
Thornton, J.,
S. Striplin,
G. S. Liu,
A. Swafford,
A. W. Stanley,
D. M. Van Winkle,
and
J. M. Downey.
Inhibition of protein synthesis does not block myocardial protection afforded by preconditioning.
Am. J. Physiol.
259 (Heart Circ. Physiol. 28):
H1822-H1825,
1990
26.
Tritto, I.,
D. D'Andrea,
N. Eramo,
A. Scognamiglio,
C. De Simone,
A. Violante,
A. Esposito,
M. Chiariello,
and
G. Ambrosio.
Oxygen radicals can induce preconditioning in rabbit hearts.
Circ. Res.
80:
743-748,
1997
27.
Vivaldi, M. T.,
R. A. Kloner,
and
F. J. Schoen.
Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats.
Am. J. Pathol.
121:
522-530,
1985[Abstract].
28.
Wyllie, A. H.,
J. F. Kerr,
and
A. R. Currie.
Cell death: the significance of apoptosis.
Int. Rev. Cytol.
68:
251-306,
1980[Medline].
29.
Yao, Z.,
and
G. J. Gross.
The ATP-dependent potassium channel: an endogenous cardioprotective mechanism.
J. Cardiovasc. Pharmacol.
4, Suppl. 4:
S28-S34,
1994.
30.
Yellon, D. M.,
A. M. Alkhulaifi,
and
W. B. Pugsley.
Preconditioning the human myocardium.
Lancet
342:
276-277,
1993[Medline].
31.
Ytrehus, K.,
Y. Liu,
and
J. M. Downey.
Preconditioning protects ischemic rabbit heart by protein kinase C activation.
Am. J. Physiol.
266 (Heart Circ. Physiol. 35):
H1145-H1152,
1994
This article has been cited by other articles:
![]() |
G. C. Sparagna, C. E. Jones, and D. L. M. Hickson-Bick Attenuation of fatty acid-induced apoptosis by low-dose alcohol in neonatal rat cardiomyocytes Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2209 - H2215. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Argaud, A.-F. Prigent, L. Chalabreysse, J. Loufouat, M. Lagarde, and M. Ovize Ceramide in the antiapoptotic effect of ischemic preconditioning Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H246 - H251. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ichinose, H. Yonemochi, T. Sato, and T. Saikawa Diazoxide triggers cardioprotection against apoptosis induced by oxidative stress Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2235 - H2241. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ohnuma, T. Miura, T. Miki, M. Tanno, A. Kuno, A. Tsuchida, and K. Shimamoto Opening of mitochondrial KATP channel occurs downstream of PKC-epsilon activation in the mechanism of preconditioning Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H440 - H447. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Liu, H. Y. Zhang, X. Zhu, Z. Shao, and Z. Yao Preconditioning blocks cardiocyte apoptosis: role of KATP channels and PKC-epsilon Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1380 - H1386. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Liu, B. C. McPherson, and Z. Yao Preconditioning attenuates apoptosis and necrosis: role of protein kinase C{epsilon} and -{delta} isoforms Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H404 - H410. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. O'Rourke Myocardial KATP Channels in Preconditioning Circ. Res., November 10, 2000; 87(10): 845 - 855. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |